- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04868669
Improving Maternal Nutrition in Matlab (IMNiM)
In-home, Intensive Nutrition Counseling to Improve Gestational Weight Gain in Rural Bangladesh: A Cluster-Randomized Controlled Trial
Background: Maternal undernutrition and inadequate gestational weight gain (GWG) are prevalent in rural communities of low- and middle-income countries (LMICs). In Matlab, Bangladesh, 54% of the women fail to gain adequate weight (>4 kg) in the third trimester. Risks associated with inadequate GWG include giving birth to a small-for-gestational age (SGA) infant, low birth weight (LBW) infant, preterm birth (PTB), etc. Few contemporary studies examined the efficacy of nutrition counseling on GWG improvement in LMICs.
Objectives: The primary objective of this study is to assess whether in-home, intensive nutrition counseling during pregnancy, compared to standard antenatal care, could improve GWG among pregnant women in rural Bangladesh.
Methods: This prospective, two-arm, parallel group, equal allocation, open-label, community-based, cluster-randomized controlled trial will be conducted in the icddr,b service area of Matlab, a rural subdistrict of Bangladesh. Clusters will be randomly allocated 1:1 to the intervention arm in which pregnant women will receive monthly in-home, intensive nutrition counseling or the control arm in which pregnant women will receive standard antenatal care as offered by icddr,b and Govt. facilities. Fixed Site Clinics (FSCs) located at the homes of the community health research workers (CHRWs) will act as clusters. Of the 33 FSCs serving rural areas in the icddr,b service area, 20 will be selected randomly and listed. These 20 clinics will then be randomly allocated 1:1 to either an intervention or control group using a computer-generated random allocation sequence. To fulfil the required sample size, each selected CHRW will enroll 16 consecutive pregnancies. Required sample size is 16 women per cluster i.e. 160 women per arm. Eligible participants will be enrolled upon obtaining their consent by 13 and 6/7 weeks of gestation (first trimester) and followed up to 6 weeks postpartum. Trained health workers will visit the homes of the women in the intervention arm once a month and provide nutrition counseling to the women and her influential family members such as mothers, mothers-in-law and husbands. Both intention-to-treat and per-protocol analyses will be performed.
Outcome measures/variables: Proportion of women with inadequate rate of weight gain in the second and third trimester of pregnancy according to the US Institute of Medicine (IOM) 2009 guidelines is the primary outcome variable.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Chandpur, Bangladesh
- International Centre for Diarrhoeal Disease Research, Bangladesh
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Pregnant women permanently residing in the icddr,b service area of Matlab fulfilling the following criteria:
Inclusion Criteria:
- aged 18-39 years
- in the first trimester of pregnancy (before 14 weeks of gestation)
- BMI 16-24.99 kg/m^2 measured on enrollment
- willing to participate in the study
Exclusion criteria
- multiple pregnancy (carrying two or more fetuses)
- threatened abortion, persistent pervaginal bleeding, or cervical incompetence
- history of three or more consecutive abortions
- history of gestational diabetes, macrosomia, gestational hypertension, preeclampsia/eclampsia in a prior pregnancy
- chronic diseases, such as hypertension, heart disease, chronic obstructive pulmonary disease, chronic kidney disease, chronic liver disease, pancreatic diseases, Crohn's disease, ulcerative colitis, diabetes mellitus, thyroid dysfunction, immunological diseases, malignancy or any other diseases which could impede compliance with the study protocol
- taking medications known to influence fetal growth, such as insulin, thyroid hormones, glucocorticoids
- known case of serious psychiatric or behavioral disorders, such as schizophrenia, bipolar disorder
- scored as moderate or worse on enrollment on any one of the subscales of the Depression, Anxiety and Stress Scales-21 (DASS-21)
- inability to read or write Bengali
- belonging to moderately or severely food insecure households as measured by the Household Food Insecurity Access Scale (HFIAS)
- having a plan to move or deliver outside the study area
- women practicing some form of vegetarianism
- women belonging to a household from which another woman is already enrolled in the study
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Investigación de servicios de salud
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Intervention
In this arm, pregnant women, along with their influential family members such as mothers, mothers-in-law, and husbands, will receive monthly in-home, intensive nutrition counseling during the prenatal period.
|
|
|
Sin intervención: Control
Pregnant women in this arm will receive standard antenatal care.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
proportion of women with inadequate rate of weight gain in the second and third trimester of pregnancy according to IOM 2009 guidelines
Periodo de tiempo: Pre-delivery
|
Pregnancy trimesters are defined as follows: 1st trimester (0 weeks - 13+6 weeks), 2nd trimester (14 completed weeks - 27+6 weeks), and 3rd trimester (28 completed weeks - childbirth).
Rate of weight gain between two time points (trimesters) will be calculated by subtracting the weight measured at the first time point from the weight measured at the second time point and dividing the derived value by the difference in weeks between the two time points.
|
Pre-delivery
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
total gestational weight gain (kg)
Periodo de tiempo: pre-delivery
|
pre-delivery
|
|
|
rate of weight gain during the 2nd and 3rd trimester (kg/week)
Periodo de tiempo: pre-delivery
|
pre-delivery
|
|
|
proportion of women with inadequate total GWG according to IOM criteria
Periodo de tiempo: pre-delivery
|
pre-delivery
|
|
|
proportion of women with inadequate total GWG according to local criteria
Periodo de tiempo: pre-delivery
|
pre-delivery
|
|
|
proportion of women with inadequate third trimester weight gain according to local criteria
Periodo de tiempo: pre-delivery
|
pre-delivery
|
|
|
proportion of preterm births
Periodo de tiempo: at delivery
|
childbirth before 37 completed weeks
|
at delivery
|
|
maternal mid-upper arm circumference (MUAC) (mm)
Periodo de tiempo: baseline, 36 weeks of gestation, at delivery and 6 weeks post-partum
|
baseline, 36 weeks of gestation, at delivery and 6 weeks post-partum
|
|
|
maternal weight (kg)
Periodo de tiempo: baseline, 36 weeks of gestation, pre-delivery, at delivery and 6 weeks post-partum
|
baseline, 36 weeks of gestation, pre-delivery, at delivery and 6 weeks post-partum
|
|
|
maternal body mass index (BMI) (kg/m^2)
Periodo de tiempo: baseline, 36 weeks of gestation, pre-delivery, at delivery and 6 weeks post-partum
|
weight and height (at baseline) will be combined to report BMI
|
baseline, 36 weeks of gestation, pre-delivery, at delivery and 6 weeks post-partum
|
|
infant weight (g)
Periodo de tiempo: at birth (delivery) and after 4 weeks
|
at birth (delivery) and after 4 weeks
|
|
|
infant length (cm)
Periodo de tiempo: at birth (delivery) and after 4 weeks
|
at birth (delivery) and after 4 weeks
|
|
|
infant head circumference (cm)
Periodo de tiempo: at birth (delivery) and after 4 weeks
|
at birth (delivery) and after 4 weeks
|
|
|
proportion of low birth weight (< 2500 g) infants
Periodo de tiempo: at birth (delivery)
|
at birth (delivery)
|
|
|
proportion of small for gestational age (<10th percentile) infants according to Intergrowth-21st standards
Periodo de tiempo: at birth (delivery)
|
at birth (delivery)
|
|
|
proportion of women with pregnancy complications e.g. anemia, preeclampsia
Periodo de tiempo: at delivery
|
at delivery
|
|
|
proportion of women with obstetric complications e.g. induction of labor, caesarean section
Periodo de tiempo: at delivery
|
at delivery
|
|
|
newborn Apgar score
Periodo de tiempo: at birth (delivery)
|
at birth (delivery)
|
|
|
proportion of infants developing morbidity
Periodo de tiempo: 4 weeks after birth
|
4 weeks after birth
|
|
|
proportion of infant mortality
Periodo de tiempo: 4 weeks after birth
|
4 weeks after birth
|
|
|
dietary diversity score according to the "Guidelines for Measuring Household and Individual Dietary Diversity"
Periodo de tiempo: baseline, 36 weeks of gestation and 6 weeks post-partum
|
score range: 0-9; higher scores indicate a better outcome
|
baseline, 36 weeks of gestation and 6 weeks post-partum
|
|
dietary diversity score according to the "Minimum Dietary Diversity for Women: A Guide to Measurement"
Periodo de tiempo: baseline, 36 weeks of gestation and 6 weeks post-partum
|
score range: 0-10; higher scores indicate a better outcome
|
baseline, 36 weeks of gestation and 6 weeks post-partum
|
|
proportion of women with inadequate dietary diversity accroding to the "Minimum Dietary Diversity for Women: A Guide to Measurement"
Periodo de tiempo: baseline, 36 weeks of gestation and 6 weeks post-partum
|
score range: 0-10; <5 indicates inadequate dietary diversity
|
baseline, 36 weeks of gestation and 6 weeks post-partum
|
|
energy consumption (kcal)
Periodo de tiempo: baseline, 36 weeks of gestation and 6 weeks post-partum
|
baseline, 36 weeks of gestation and 6 weeks post-partum
|
|
|
protein consumption (g)
Periodo de tiempo: baseline, 36 weeks of gestation and 6 weeks post-partum
|
baseline, 36 weeks of gestation and 6 weeks post-partum
|
|
|
proportion of women with symptoms of depression as measured by Depression, Anxiety, and Stress Scales-21 (DASS-21) scales
Periodo de tiempo: baseline, 36 weeks of gestation and 6 weeks post-partum
|
DASS-21 is a validated, widely used, standardized self-report scale with 7 items in each subscale category of Depression, Anxiety, and Stress symptoms.
Responses are scored on a 4-point Likert scale ranging from 0 (did not apply to me at all) to 3 (applied to me very much/most of the time), with higher scores indicating higher levels of depression, anxiety or stress.
|
baseline, 36 weeks of gestation and 6 weeks post-partum
|
|
proportion of women with symptoms of anxiety as measured by Depression, Anxiety, and Stress Scales-21 (DASS-21) scales
Periodo de tiempo: baseline, 36 weeks of gestation and 6 weeks post-partum
|
DASS-21 is a validated, widely used, standardized self-report scale with 7 items in each subscale category of Depression, Anxiety, and Stress symptoms.
Responses are scored on a 4-point Likert scale ranging from 0 (did not apply to me at all) to 3 (applied to me very much/most of the time), with higher scores indicating higher levels of depression, anxiety or stress.
|
baseline, 36 weeks of gestation and 6 weeks post-partum
|
|
proportion of women with symptoms of stress as measured by Depression, Anxiety, and Stress Scales-21 (DASS-21) scales
Periodo de tiempo: baseline, 36 weeks of gestation and 6 weeks post-partum
|
DASS-21 is a validated, widely used, standardized self-report scale with 7 items in each subscale category of Depression, Anxiety, and Stress symptoms.
Responses are scored on a 4-point Likert scale ranging from 0 (did not apply to me at all) to 3 (applied to me very much/most of the time), with higher scores indicating higher levels of depression, anxiety or stress.
|
baseline, 36 weeks of gestation and 6 weeks post-partum
|
|
healthcare seeking and services utilization e.g. number of prenatal visits
Periodo de tiempo: at delivery
|
at delivery
|
Colaboradores e Investigadores
Investigadores
- Investigador principal: S. M. Tafsir Hasan, MBBS, MS, Nutrition and Clinical Services Division, icddr,b
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- PR-19109
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .